End in sight for US ban on unapproved devices literature
This article was originally published in Clinica
The US FDA has indicated it may lift its prohibition on manufacturers' dissemination of textbooks and peer-reviewed articles that describe unapproved uses of medical devices. The agency last week announced that it "has determined that distribution [to healthcare professionals] of textbooks that do not highlight unapproved uses should be permitted. Similarly ... the FDA has determined that certain peer-reviewed journal reports upon which FDA relied for approval of a product may be distributed even if they contain information (eg reference to unapproved uses) that is inconsistent with the FDA-approved labelling for the product."
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.